Medical Specialist: Grade 1 to 3 (Nuclear Medicine) at Western Cape Department of Health and Wellness

REQUIREMENTS :

• Minimum educational qualification:
• Appropriate qualification that allows registration with the Health Professional Council of South Africa (HPCSA) as a Medical Specialist in Nuclear Medicine.
• Registration with a professional council: Registration with the HPCSA as a Medical Specialist in Nuclear Medicine.

Experience:

Grade 1:

• None after registration with the HPCSA as Medical Specialist in Nuclear Medicine.

Grade 2:

• A minimum of 5 years’ appropriate experience as Medical Specialist after registration with the HPCSA (or recognised foreign Health Professional Council in respect of foreign qualified employees) as Medical Specialist in Nuclear Medicine.

Grade 3:

• A minimum of 10 years’ appropriate experience as Medical Specialist after registration with the HPCSA (or recognised foreign Health Professional Council in respect of foreign qualified employees) as a Medical Specialist in Nuclear Medicine.
• Inherent requirement of the job:
• A valid driver`s license.

Competencies (knowledge/skills):

• Ability to work in a team. Experience in management of general nuclear medicine, PET/CT imaging and radio nuclide therapy.
• Computer literacy, database management.
• Strong moral and ethical record in nuclear medicine.
• The ability to work in a busy tertiary care hospital providing specialist paediatric nuclear medicine services.
• Ability to supervise registrars and other related trainees in acquiring paediatric nuclear medicine skills.
• Strong academic record in terms of teaching and research supported by courses, publications and presentations.
• Commitment to attaining and teaching advanced skills in nuclear medicine.
• Sound clinical knowledge and skills in Nuclear Medicine. molecular imaging and targeted radionuclide therapy.
• Ability to work in a multi-disciplinary team.
• Knowledge of legislation, policies and procedures pertaining to radiopharmaceuticals, their theragnostic applications and clinical trial framework.

CLOSING DATE : 30 January 2026